Pfizer and Novartis are notable market players in epilepsy therapeutics.

1 report, 1 independent Updated Jul 18

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Pfizer Novartis

Keep exploring

Part of

Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.

Also in this story

Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.Jun 7

All 4 developments

The entities involved

Pfizer
American multinational pharmaceutical and biotechnology corporation
- Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
Novartis
Swiss-American multinational pharmaceutical corporation
- Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
- GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16

Related events

Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.Jun 7

Coverage

Newest first; wire copies grouped

Jul 18GlobeNewswireEpilepsy Therapeutics Market Trends, Competitive Strategies and Forecasts Report 2025-2033 | Personalized Medicine Paves New Pathways in Treatment, Third-Generation Therapeutics Lead Growth The epile